Vistagen Therapeutics, Inc. · NASDAQ:VTGN
Vistagen Therapeutics — Investor Presentation (January 2019)
34 slides from Vistagen Therapeutics's investor presentation, Jan 11, 2019
Slide 1: Corporate Presentation January 2019
oy VistaGene Therapeutics DEVELOPING NEXT GENERATION MEDICINES FOR Se CNS DISEASES AND DISORDERS ) WITH HIGH UNMET NEED *, = Corporate Presentation g® Nasdaq:vten January 2019 San Francisco, California
Slide 2: Forward-looking Statements
a Forward-looking VistaGens_ Statements
Slide 3: VistaGen Overview
i om | VistaGen Overview _ NASDAQ: VTGN A ag CNS -tocused, ctinical-stage (in or through Phase 2 clinical development) a) 3 novel CNS candidates, 2 with Phase 2 POC efficacy data, each with fast-acting O: activity and potential to be safer and better tolerated than current drugs fg 5 large and addre
Slide 4: Pipeline
eretagenson Pipeline — Social Anxiety Disorder ‘Major Depressive Disorder’ ‘Major Depressive Disorder Suicidal deation [Neuropathic Pain Parkinson's Disease Dyskinesia 2 | ‘Major Depressive Disorder | a
Slide 5: Social Anxiety Disorder
Ke) VistaGene Therapeutics Social Anxiety Disorder _——— [M nasdaq:vton
Slide 6: Social Anxiety Disorder in the U.S.
VistaGen. i Social Anxiety Disorder in the U.S. a Intense, persistent fear of being watched and judged by others, causing people to avoid everyday social situations for fear of being scrutinized, judged, humiliated or embarrassed Seaavanempisnies ahaa tier fc la ental ath BPG nthe yg ‘or a socal and
Slide 7: Current Drug Treatments for SAD Fall Short
Ke. VistaGen. Current Drug Treatments for SAD Fall Short FDA, Off-label APPROVED Antidepressants Benzodiazepines such as alprazolam (Xanax) SSRis such as paroxetine and sertraline Addiction and SNRis such as venlafaxine oes Sedation Take weeks to months to work and cognition ipatmant SY SO Saray Bet
Slide 8: PH94B: Novel, Fast-Acting, On-Demand Treatment for SAD
| PH94B Novel, Fast-Acting, On-Demand Treatment for SAD Phase 3-ready ¥ First-in-class, synthetic neurosteroid 7 Novel MOA targets nasal chemosensory hheurons in the amygdala to suppress anxiety ¥ Self-administered on-demand, as needed (PRN) prior to a feared event Y Microdose (3.2 ug) delivered dir
Slide 9: PH94B Phase 2 Efficacy Data
9 i PH94B Phase 2 Efficacy Data I + Multicenter, randomized, double-blind, placebo-controlled, single-dose study (n=91) + Significantly and rapidly reduced anxiety produced by laboratory- simulated public speaking and social interaction challenges in female SAD patients + Well-tolerated, no systemic
Slide 10: PH94B Real World Pilot Phase 2 Efficacy Data
| PH94B “Real World” Pilot Phase 3 Efficacy Data = “Real-world” placebo-controlled, cross ‘over study in patients with SAD who confronted stressful situations in their workplaces and social situations (n=22) + Significant difference observed for subjects while on PH94B vs. placebo on primary outcome
Slide 11: Major Depressive Disorder
Ke) VistaGene Therapeutics Major Depressive Disorder _——— [M nasdaq:vton
Slide 12: Depression in the U.S.
VistaGen. | Depression in the U.S. — 1in 4 women 1in6men 1in8 ee ttt ae ae RRA > PEDERDE diagnosed with depressive disorders age 12 and over takes an antidepressant’ DEPRESSION, LARGE ADDRESSABLE MARKET WITH HIGH UNMET NEED: 11.6M 7.3M 5.1M Drug-treated patients with Inadequate response” Treatment-r
Slide 13: Current Approved Drug Treatments for Depression Fall Short
Ke, VistaGen. remileogencom Current Approved Drug Treatments for Depression Fall Short Current Antidepressants Adjunctive Atypical Antipsychotics * Often do not work * Often do not work ~ First antidepressant effective in only 10f3 _— Only 10 to 20% of patients respond to patients ‘augmentation + Sl
Slide 14: Ketamine: Breakthrough in MDD Treatment
Ketamine: Breakthrough in MDD Treatment Antidepressant Effects Within 1 Day of a Single IV Infusion remileogencom ras Us neipeeketanne — BN Response Maebo fee ros at on eS Responder’ Rates at 1 Day with Ketamine in Treatment-resistant MDD 40% * Proportion of patents wth weatment- 2m resistant MOD wi
Slide 15: Potential Limitations of Long-Term Ketamine Therapy
Potential Limitations of Long-Term Ketamine Therapy ween | emveogencm “ .(lJtis necessary to recognize the major gaps that remain in cour knowledge about the longer-term efficacy and safety of [=] ketamine infusions.”* fA ‘The American Psychiatric Association (APA) Council of Research Task Force on
Slide 16: AV-101 and PH10: Beyond Ketamine for MDD
VistaGen: AV-101 and PH10 Tensile Beyond Ketamine for MDD i Ke) i [M nasdaq:vton
Slide 17: AV-101: New Generation Adjunctive Treatment for MDD
i / AV-101 ween, New Generation Adjunctive Treatment for MDD Oral NMDAR GlyB antagonist ~ ¥ Ketamine-like antidepressant effects in published Spy preclinical studies Y Well-tolerated in two Phase 1 studies and two ss ‘ongoing Phase 2 studies ¥ No psychological side effects observed to date FDA Fast
Slide 18: Initial Regulatory and Commercial Objective
el VistaGen. Initial Regulatory and Commercial Objective renee Adjunctive Treatment for Inadequate Response to SSRIs/SNRIs ‘SSRI/SNRI ‘SSRI/SNRI ‘SSRI/SNRI LITT L/ sees asspends ////// DISPLACE ATYPICAL ANTIPSYCHOTICS IN CURRENT DRUG TREATMENT PARADIGM
Slide 19: AV-101 vs. Ketamine in Published Preclinical Studies
} AV-101 vs. Ketamine in Published Preclinical Studies Rapid-acting, Antidepressant-like Effects AV-101 Forced-swim Tai-suspension Learned-helplessness Novelty-suppressed feeding Side Effects Av-101 Psychotomimetic and rewarding Hyper movement No No ‘Movement sensitization No Gircling and rearing No
Slide 20: AV-101 Published Phase 1 Safety Studies
io] AV-101 Published Phase 1 Safety Studies “see eretagenson + Two NIH-funded Phase 1 safety studies conducted in 86 normal volunteers + Phase 1A: Single ascending dose - 30 to 1440 mg of AV-101 administered once + Phase 18: Multiple ascending dose ~ 360, 1080 and 1440 mg administered daily for 14 d
Slide 21: AV-101 NIMH Phase 2 Clinical Study
VistaGen. AV-101 NIMH Phase 2 Clinical Study aaa Principal Investigator: Dr. Carlos Zarate, Jr., National Institute of Mental Health retageson + NIH-sponsored; ongoing at NIMH * Double-blind, placebo-controlled, crossover design + Monotherapy in patients with treatment-resistant depression, once per
Slide 22: AV-101 ELEVATE Phase 2 Clinical Study
AV-101 ELEVATE Phase 2 Clinical Study ve Adjunctive Treatment for Major Depressive Disorder ease Principal Investigator: Dr. Maurizio Fava, Harvard Medical School * Company-sponsored * Adjunctive treatment for inadequate response to current SSRI/SNRI therapy * Oral dose (1440 mg), once per day for 1
Slide 23: PH10: Novel, Fast-Acting Intranasal Treatment for MDD
| PH910 }) Novel, Fast-Acting Intranasal Treatment for MDD ¥ First-in-class, synthetic neurosteroid ¥ Novel MOA activates nasal chemosensory receptors that in turn engage GABA in the limbic amygdala system ¥ Self-administered, at-home ¥ Microdose (3.2 ug) delivered directly to receptors in nasal pas
Slide 24: PH10 Phase 2a Efficacy Data
el PH10 Phase 2 Efficacy Data HAM D Reduction from Baseline = sof ie Los 2 — ins # & q “15.0 7 7S: : Tei TAI TWIG DEA HWS TG TWIT TW VistaGen.
Slide 25: Potential Additional AV-101 and PH10 Depression Indications
Potential Additional AV-101 and PH10 Depression Indications + Prevent relapse following successful ketamine therapy + Front-line monotherapy
Slide 26: Suicidal Ideation
Ke) VistaGene Therapeutics Suicidal Ideation _——— [M asdaq:vten
Slide 27: Baylor / VA Phase 1b Clinical Study
remileogencom US. Department Baylor / VA Phase 1b Clinical Study @ ofNeterans Ma Investigating AV-101 as a Potential Treatment for Suicidal Ideation Principal Investigator: Dr. Marijn Lijffijt, Baylor College of Medicine = Sponsored by U.S. Department of Veteran's Affairs (VA); ongoing at Baylor Uni
Slide 28: Neuropathic Pain and Parkinson's LID
Ke) Neuropathic Pain [eee and VistaGene Parkinson’s LID |___ Therapeutics [M nasdaq:vton
Slide 29: AV-101 for Neuropathic Pain
I AV-101 for Neuropathic Pain vores. Oral, Non-opioid, Non-addictive, Non-sedating Treatment Option ‘undertaken new efforts to support novel product innovation. includes ... steps to advance the development of non-addictive treatments for pain.” -Scott Gottlieb, M.D., FDA Commissioner CREDA, | Fs er
Slide 30: AV-101 for Parkinson's Dyskinesia
eretagenson AV-101 for Parkinson’s Dyskinesia Vee Replace oral amantadine in treatment paradigm to reduce dyskinesia induced by levodopa therapy, without amantadine-like side effects Levodopa-induced dyskinesia occurs in 80% of patients with PO after 10 years AV-101 reduced mean dyskinesia scores by
Slide 31: Experienced Team
. Ke Experienced Team } Leading Execution Shawn K. Singh Chief Executive Oficer += 2s years of experience with opharmaceutal companies 2 healthcare ‘entre eaptal frm and. grftable CRO «hres Neurosence,Silone Pharmaceutialy; Cato aVentures; Cato 2B years of experienc ins + ProentorUnebergee Co Jerrol
Slide 32: Preeminent CNS Clinical and Regulatory Advisors
HARVARD. FDA Maurizio Fava, M.O. Professrof Psychiatry, Harvard Medal School, Decor, Orion of Cea Research, Massachusetts General Hoxptal GH) Reseach inte xeeutve Decor, MGM Clint re etwork a nstte Michael Liebowitz, M.D. Profesor of Clea Payee, Columba Univers: Managing ecto and Founder, The Medial
Slide 33: VistaGen Summary
remileogencom VistaGen. VistaGen Summary NASDAQ: VTGN Focused on large addressable CNS markets where current medications fall short []]—_Muttipte shots on goal with 3 late-stage CNS pipeline candidates Highly-experienced team leading execution i ; 4
Slide 34: Company Contact
\o) VistaGens ‘Therapeutics he © Company Contact: ‘Matk A. MePartiand \VistaGen Therapeutics Inc Phone: +1 (650) 577-3606 Email: R@VistaGen.com Website: won. vstagen.com DEVELOPING NEW GENERATION MEDICINES FOR DEPRESSION AND OTHER CNS DISORDERS
VistaGen Therapeutics — Investor Presentation (January 2019) on 6ix